These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 23737138)
21. Increased Serum 25(OH)D Nakamura Y; Uchiyama S; Kamimura M; Ikegami S; Komatsu M; Kato H Tohoku J Exp Med; 2017 Jul; 242(3):241-246. PubMed ID: 28740036 [TBL] [Abstract][Full Text] [Related]
22. Biological sources of variations of tartrate-resistant acid phosphatase 5b in a healthy Japanese population. Kikuchi W; Ichihara K; Mori K; Shimizu Y Ann Clin Biochem; 2021 Jul; 58(4):358-367. PubMed ID: 33715446 [TBL] [Abstract][Full Text] [Related]
23. Serum Levels of NTx and TRACP5b in Giant Cell Tumor of Bone and its Clinical Implications. Chen J; Younusi A; Cao L; Xu L; Zhou Y; Zhen T; Song X Clin Lab; 2015; 61(8):1077-81. PubMed ID: 26427154 [TBL] [Abstract][Full Text] [Related]
24. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis]. Nowak Z; Konieczna M; Wańkowicz Z Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322 [TBL] [Abstract][Full Text] [Related]
25. Influence of exercise mode and osteogenic index on bone biomarker responses during short-term physical training. Lester ME; Urso ML; Evans RK; Pierce JR; Spiering BA; Maresh CM; Hatfield DL; Kraemer WJ; Nindl BC Bone; 2009 Oct; 45(4):768-76. PubMed ID: 19520194 [TBL] [Abstract][Full Text] [Related]
26. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688 [TBL] [Abstract][Full Text] [Related]
27. Bone Mineral Density and Bone Turnover Markers Under Bisphosphonate Therapy Used in the First Year After Liver Transplantation. Nowacka-Cieciura E; Sadowska A; Pacholczyk M; Chmura A; Tronina O; Durlik M Ann Transplant; 2016 Apr; 21():241-9. PubMed ID: 27112626 [TBL] [Abstract][Full Text] [Related]
28. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775 [TBL] [Abstract][Full Text] [Related]
30. Serum tartrate-resistant acid phosphatase 5b or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate therapy in postmenopausal osteoporosis? Välimäki MJ; Tähtelä R Clin Chem; 2005 Dec; 51(12):2382-5. PubMed ID: 16306104 [No Abstract] [Full Text] [Related]
31. Bone formation is suppressed with multi-stressor military training. Hughes JM; Smith MA; Henning PC; Scofield DE; Spiering BA; Staab JS; Hydren JR; Nindl BC; Matheny RW Eur J Appl Physiol; 2014 Nov; 114(11):2251-9. PubMed ID: 25027064 [TBL] [Abstract][Full Text] [Related]
32. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257 [TBL] [Abstract][Full Text] [Related]
33. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker. Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715 [TBL] [Abstract][Full Text] [Related]
34. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403 [TBL] [Abstract][Full Text] [Related]
35. Usefulness of bone resorption markers in hemodialysis patients. Hamano T; Tomida K; Mikami S; Matsui I; Fujii N; Imai E; Rakugi H; Isaka Y Bone; 2009 Jul; 45 Suppl 1():S19-25. PubMed ID: 19332165 [TBL] [Abstract][Full Text] [Related]
36. Effect of continuous long-term treatment for 10 years with bisphosphonate on Japanese osteoporosis patients. Iba K; Takada J; Sonoda T; Yamashita T J Bone Miner Metab; 2020 Mar; 38(2):240-247. PubMed ID: 31667583 [TBL] [Abstract][Full Text] [Related]
37. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis? Avbersek-Luznik I; Balon BP; Rus I; Marc J Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031 [TBL] [Abstract][Full Text] [Related]
38. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290 [TBL] [Abstract][Full Text] [Related]
39. [Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab]. Tatekoshi A; Sato T; Ibata S; Hashimoto A; Kamihara Y; Horiguchi H; Ono K; Takada K; Iyama S; Takimoto R; Kobune M; Kato J Rinsho Ketsueki; 2014 Nov; 55(11):2271-6. PubMed ID: 25501406 [TBL] [Abstract][Full Text] [Related]
40. Vitamin D status and markers of bone turnover in Caucasian and South Asian postmenopausal women living in the UK. Lowe NM; Mitra SR; Foster PC; Bhojani I; McCann JF Br J Nutr; 2010 Jun; 103(12):1706-10. PubMed ID: 20102676 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]